Vystar to Produce RxAir400 UV-C Light Air Purifiers with New Manufacturer
- CDC reports UV-C Light Germicidal Irradiation (UVGI) as one of “most promising methods" for Coronavirus decontamination of facemasks.1
- RxAir400 employs powerful UVGI proven to inactivate >99.9% of viruses and pathogens
- Reduces virus exposure risk in schools, restaurants, retail and office facilities
Worcester, MA, July 16, 2020 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) has restarted production of its RxAir400 Ultraviolet (UV) light air purification systems with a new manufacturer that will enable enhanced reliability for supply chain,
production and delivery. RxAir400 is a smaller, consumer/small business-sized version of the industrial size Rx3000 FDA-certified Class II medical device UV light air purifier designed for
disinfection use in hospitals. Vystar anticipates receiving the first shipment of 10,000 RxAir400 units and replacement bulb cartridges from the new manufacturer in approximately 45 days. Vystar is
currently taking pre-orders on its RxAir.com website. It has received cash deposits on pre-orders of approximately $1 million of RXAir products at retail.
“Our new manufacturer, UV-C light bulb supplier and other suppliers resumed operations after coordinating with health officials to ensure proper COVID-19 protocols for employee and customer safety,” stated Steve Rotman, Vystar CEO. “Many companies now offer UV-light products, but as the CDC1 and Live Science2 reported, ‘it takes the right kind of UV in the right dosage’ to be effective. RxAir’s ViraTech UV-C light delivers the right kind and dosage to inactivate numerous Coronavirus strains.”
Due to its ability to combat airborne pathogens on a continuous basis and complement surface and personal sanitation protocols, RxAir400 reduces risk of exposure to harmful viruses in facilities such as:
- Medical offices,
- Hotels, and
“Given the growing body of evidence that Coronavirus SARS CoV-2 may be transmitted through airborne means or aerosolization noted by the CDC1, an open letter to the World Health organization by 239 scientists published in Clinical Infectious Diseases4, and articles in Emerging Infectious Diseases3 and Nature Magazine5, it is wise to address all modes of possible transmission,” stated Bryan Stone, MD, Internal Medicine and Nephrology, Chief of Medicine for Desert Regional Medical Center.